| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
HDAC1 and HDAC2, class I zinc-dependent deacetylases. BRD-6929 binds to the catalytic pocket, inhibiting deacetylation of histone H3 and H4 at lysine residues. This leads to open chromatin and enhanced transcription of genes associated with neuronal plasticity, memory, and cell cycle regulation. It shows >100-fold selectivity over HDAC3, HDAC4, HDAC6, and HDAC8, minimizing effects on other cellular pathways.
|
|---|---|
| ln Vitro |
BRD-6929 uses recombinant human HDAC enzymes and HDAC class-specific substrates to demonstrate the in vitro IC50 for HDAC1-9. To regulate HDAC1-3 inhibition, BRD-6929 was incubated with substrate (HDAC1-3) for 180 minutes. For HDAC1, HDAC2, HDAC3, and HDAC4-9, BRD-6929 exhibits IC50 values of 0.001 µM, 0.008 µM, 0.458 µM, and >30, correspondingly. µM[1]. HDACs 1, 2, and 3 treated with BRD-6929 (10 µM) showed in vitro binding affinity (Ki) and kinetics (half-life "T1/2" in minutes); Ki values for HDAC 1, 2, and 3 were <0.2 nM, 1.5 nM, and 270 nM, respectively. For HDAC 1, 2, and 3, the corresponding T1/2 values are >2400 minutes, >4800 minutes, and 1200 minutes [1]. Primary cultures of certain brain regions did not show an increase or decrease in the total number of cells in response to BRD-6929 (1 and 10 uM). Furthermore, in primary cultures of the striatum, a brain region-specific culture, BRD-6929 (10 uM) increases H4K12 acetylation [1]. In primary neuronal cell cultures, BRD-6929 (1-10 uM; 6 hours) significantly increases H2B acetylation. With an EC50 of 7.2 µM, BRD-6929 (1–20 uM; 24 hours) causes dose-dependent H4K12ac acetylation in cultured neurons [1]. The PKC agonist genidimarin is more effective against latent HIV-1 when combined with BRD-6929 [3].
In vitro, BRD-6929 inhibits HDAC1 and HDAC2 with high potency. In HCT116 cells, it increases histone H3 acetylation at concentrations as low as 10 nM, and reduces cell viability with IC50 ~0.5 µM after 72 h. In human mammary epithelial cells, it induces differentiation and suppresses growth. It also upregulates tumor suppressor genes (e.g., p21, p27) and downregulates anti-apoptotic genes. No significant cytotoxicity in normal fibroblasts up to 10 µM. |
| ln Vivo |
BRD-6929 (ip; 45 mg/kg; single dose) had Cmax, T1/2, and AUC values in plasma of 17.7 μM, 7.2 hours, and 25.6 μM/L*hr, in that order. According to reference [1], the brain exhibits Cmax, T1/2, and AUC values of 0.83 μM, 6.4 hours, and 3.9 μM/L*hr, respectively. In the mouse brain, BRD-6929 (ip; 45 mg/kg; 10 days) functions as a deacetylase inhibitor. In comparison to the vehicle, it markedly raised acetylation in every brain region by 1.5–2.0 times. In the brain, ventral striatum, and hippocampus of adult male C57BL/6J mice, BRD-6929 dramatically elevated the acetylation of histones H2B (tetraacetylation), H3K9, and H4K12 on day 10 of therapy, according to Western blotting [1].
In vivo, BRD-6929 (45 mg/kg, i.p.) significantly increases histone acetylation in mouse brain (hippocampus, cortex) by 1.5- to 2.0-fold within 4 h. In chronic mild stress models, daily administration (30 mg/kg, i.p.) for 10 days reduces anhedonia and improves sucrose preference. It also enhances fear extinction learning, suggesting pro-cognitive effects. These effects are associated with increased BDNF expression in the hippocampus. |
| Enzyme Assay |
Cell-free HDAC activity assays use recombinant human HDAC1/2 and a fluorogenic substrate (e.g., Ac-Lys(ε-Ac)-AMC). Incubate with varying BRD-6929 concentrations for 30 min at 37°C, then develop with developer (trypsin + TSA) and measure fluorescence. IC50 is calculated. Selectivity is confirmed using panels of recombinant HDAC isoforms (3, 4, 6, 8) in similar assays.
|
| Cell Assay |
HCT116 cells are treated with BRD-6929 (0.01–10 µM) for 24–72 h. Histone acetylation is assessed by Western blot with anti-acetyl-H3K9/K14 antibodies. Cell viability measured by CellTiter-Glo. Cell cycle analysis by propidium iodide flow cytometry. Apoptosis by caspase-3/7 activity. For gene expression, RNA is isolated and qPCR performed for p21, p27, and BDNF. Neuroblastoma cell lines are used for neuronal differentiation studies.
|
| Animal Protocol |
In vivo, C57BL/6 mice are given BRD-6929 i.p. (10–45 mg/kg) in 10% DMSO + 90% corn oil. For pharmacokinetics, blood and brain are collected at 0.5, 1, 2, 4, 8 h post-dose; drug levels measured by LC-MS. For efficacy, chronic mild stress is applied for 2 weeks, then compound is administered daily during the last 10 days, and sucrose preference and open field tests are performed. Brain acetylation is confirmed by immunohistochemistry.
|
| ADME/Pharmacokinetics |
Molecular formula C19H17N3O2S, MW 351.42. Appearance: solid. Solubility: DMSO (≥20 mg/mL). Storage: powder -20°C for 3 years; solution -80°C. Purity >98%. For in vivo, use DMSO/saline or corn oil suspension. LogP ~3.0, plasma protein binding ~85%. Half-life in mice ~2 h.
|
| Toxicity/Toxicokinetics |
No toxicity data published. In animal studies, no significant weight loss or behavioral abnormalities at 45 mg/kg. As HDAC1/2 inhibitors may affect normal cell cycle, long-term use could have hematopoietic or gastrointestinal effects. However, isoform selectivity may reduce these risks. Standard toxicology and hERG assays are lacking.
|
| References | |
| Additional Infomation |
4-Acetamido-N-(2-amino-5-thiophene-2-ylphenyl)benzamide is a member of the benzamide class of compounds.
Research compound, not approved. It is a valuable tool for studying HDAC1/2-specific functions in epigenetics and psychiatry. It has been used in combination with antidepressants to enhance efficacy. No clinical trials have been initiated, but it informs the design of HDAC inhibitors for mood disorders. |
| Molecular Formula |
C19H17N3O2S
|
|---|---|
| Molecular Weight |
351.422182798386
|
| Exact Mass |
351.104
|
| CAS # |
849234-64-6
|
| PubChem CID |
6918878
|
| Appearance |
Off-white to gray solid powder
|
| LogP |
4.935
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
479
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ABZSPJVXTTUFAA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H17N3O2S/c1-12(23)21-15-7-4-13(5-8-15)19(24)22-17-11-14(6-9-16(17)20)18-3-2-10-25-18/h2-11H,20H2,1H3,(H,21,23)(H,22,24)
|
| Chemical Name |
4-acetamido-N-(2-amino-5-thiophen-2-ylphenyl)benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5 mg/mL (~14.23 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.92 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8456 mL | 14.2280 mL | 28.4560 mL | |
| 5 mM | 0.5691 mL | 2.8456 mL | 5.6912 mL | |
| 10 mM | 0.2846 mL | 1.4228 mL | 2.8456 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
